百力司康 (Bailisikan) is a clinical-stage biopharmaceutical company founded in December 2017 in Hangzhou, focused on developing innovative antibody-drug conjugates (ADCs). Its lead candidate, BB-1701, is an Eribulin-based ADC undergoing a China–U.S. combined Phase I study; the Eribulin payload was licensed from Japan's Eisai and has established clinical safety and efficacy. The company holds global development and commercialization rights for BB-1701 and plans a second Eribulin ADC, BB-1705, with dual China–U.S. filings expected this year. 百力司康 also claims a proprietary site-specific conjugation technology and is advancing multiple best-in-class and first-in-class programs in its pipeline. Proceeds from the recent financing will support international multicenter clinical development of BB-1701, preclinical and registration work for other programs, and construction of R&D and manufacturing facilities.

Total raised

$61M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2021